TMO

Thermo Fisher Scientific Inc. - 10-Q Summary (Q2 2007)

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2007. Thermo Fisher Scientific Inc. operates in two primary segments: Analytical Technologies and Laboratory Products and Services. The financial results are significantly impacted by the November 2006 merger with Fisher Scientific International Inc., which is now fully consolidated. The company is a large accelerated filer incorporated in Delaware.

Key Financial Metrics

Note: Debt figures represent the sum of short-term obligations ($24.8M) and long-term obligations ($2,177.7M) as of June 30, 2007.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 234% in Q2 and 238% YTD compared to the prior year. This growth is primarily attributable to the inclusion of Fisher Scientific International Inc. following the merger, alongside organic growth and favorable currency translation.
• Profitability: Net income increased 242% in Q2 and 219% YTD. Operating income margins remained relatively stable in Q2 (10.2% vs 10.1%) but decreased slightly YTD (9.2% vs 10.0%) due to significant non-cash charges.
• Amortization Impact: Operating income was reduced by $142.1 million in Q2 and $281.4 million YTD due to the amortization of acquisition-related intangible assets from the Fisher merger and other acquisitions.
• Inventory Revaluation: The company recorded $11.2 million in Q2 and $47.6 million YTD in charges to cost of revenues for the sale of inventories revalued at the date of the Fisher acquisition.
• Discontinued Operations: A non-cash after-tax impairment charge of $27 million was recorded related to the required divestiture of the GVI business by the UK Competition Commission.

Guidance, Outlook, and Risks

• Tax Rate Outlook: Management expects the full-year effective tax rate to be approximately 16%. A one-time reduction to the income tax provision of $15–$20 million is anticipated in Q3 2007 due to new tax legislation in the UK and Germany.
• Capital Expenditures: The company expects 2007 capital expenditures to approximate $200–$250 million.
• Restructuring: The company is finalizing restructuring plans related to the Fisher merger, which may include facility consolidations and staffing reductions. Future charges for a potential facility closure in France are estimated at $16–$18 million.
• Acquisitions: The company agreed to acquire Qualigens Fine Chemicals (GSK India) for approximately $60 million, expected to close in Q4 2007.
• Risks: Key risks include the successful integration of the Fisher merger, potential impairment of goodwill ($8.55 billion), intellectual property litigation (specifically regarding mass spectrometers), and exposure to currency exchange rate fluctuations.

Investor Verification Checklist

• Merger Integration: Verify the realization of anticipated synergies and cost savings from the Fisher Scientific merger against the high amortization and restructuring costs.
• Goodwill Valuation: Monitor the $8.55 billion goodwill balance for potential impairment triggers, especially given the required divestiture of the GVI business.
• Discontinued Operations: Confirm the final disposal value and timeline for the GVI divestiture mandated by the UK Competition Commission.
• Tax Position: Review the impact of the UK and German tax rate changes on deferred tax balances and the projected $15–$20 million Q3 benefit.
• Litigation Exposure: Assess the status of the patent infringement lawsuit filed by Applera Corporation/MDS Inc. regarding mass spectrometer systems.